Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Times cited: 4
- Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 2016 In Process GET IT
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
The Lancet. Oncology.
Times cited: 210
Enzalutamide in European and North American men participating in the AFFIRM trial.
Times cited: 6
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology. 2014 Information Resource GET IT
- Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine. 2014 Academic Article GET IT